|
 |
|
|
|
|
|
Speakers The speaker panel for the Cell & Gene Therapy Forum 2009 is now almost complete. Amongst those high profile figures who have already confirmed their participation are: Dr Karen Kozarsky, Head, Gene Therapy, Biopharmaceutical Center of Excellence for Drug Discovery, GlaxoSmithKline Kimberly A. Benton, PhD, Deputy Director, Division of Cellular & Gene Therapies, OCTGT/CBER, US Food & Drug Administration Alain A.G. Vertès, PhD, MBA, Global Alliance Director, Pharmaceuticals Division, Pharma Partnering, F. Hoffmann-La Roche Ltd Professor Ryuichi Morishita, Professor, Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine & Board Member, AnGes MG Dr C. Randal Mills, President & CEO, Osiris Therapeutics, Inc Stacey Davis, Principal, Venture Investments, Johnson & Johnson Development Corporation Dr Philip G. Vanek, Head of Business Development, Cell Therapy, Lonza Walkersville, Inc Stephen Potter, Senior Vice President, Corporate Development, Genzyme Corporation Dr Rajesh Chopra, Global Medical Science Director, Emerging Products, AstraZeneca Dr Gopalan Narayanan, Manager & Head, Biologicals & Biotechnology Unit, Medicines & Healthcare Products Regulatory Agency (MHRA) Dr John McNeish, Executive Director, Regenerative Medicine, Pfizer Inc Shosh Merchav, PhD, MBA, Director, Head, Cell Therapy Projects, Teva Innovative Ventures, Teva Pharmaceutical Industries Ltd Edward Lanphier, President & CEO, Sangamo BioSciences, Inc David L. Amrani, PhD, FAHA, Senior Director, Research & Development Lead, Cellular Therapies, Baxter Healthcare Corporation Dr Jane S. Lebkowski, Senior Vice President, Regenerative Medicine, Geron Corporation Geoff Mackay, President & CEO, Organogenesis Inc Dr Jeffrey M. Ostrove, President & CEO, Ceregene, Inc Dr Leonide C. Saad, Vice President, Proteus Venture Partners Dr Daniel Takefman, Chief, Gene Therapy Branch, Division of Cellular & Gene Therapy, OCTGT/CBER, US Food & Drug Administration Brock C. Reeve, Executive Director, Harvard Stem Cell Institute Dr Moshe Flugelman, President, CTO & Co-Founder, MGVS Robert C. Moen, MD, PhD, President & CEO, Copernicus Therapeutics, Inc Dr Ann Tsukamoto, Vice President, R&D, StemCells, Inc Eric C. Faulkner, Senior Director, US Market Access & Reimbursement, RTI Health Solutions Chris Lockett, Senior Director of Government Affairs, Dendreon Corporation Dr Geert-Jan Mulder, General Partner, Forbion Capital Partners Dean Miller, Managing Director, Novitas Capital Dr Gil Van Bokkelen, Chairman & CEO, Athersys, Inc Ed Field, President & COO, Aldagen, Inc Howard J. Leonhardt, Chairman, Chief Executive Officer & Chief Technology Officer, Bioheart, Inc Gary C. du Moulin, PhD, MPH, Senior Director, Quality Compliance, Genzyme Biosurgery Dr Mark Scheideler, Senior Scientific Officer, Roadmap Initiatives, National Institute of Neurological Disorders & Stroke, National Institutes of Health Dr Stuart Naylor, Chief Scientific Officer, Oxford Biomedica (UK) Ltd Karl Groth, PhD, Co-founder, Ascent Private Equity Dr Gary McGarrity, Executive Vice President of Scientific & Clinical Affairs, VIRxSYS Dr Tracey Lodie, Associate Director, MSC Program Head, Genzyme Corporation Dr Doug Jolly, Executive Vice President of Research & Product Development, Tocagen Inc Dr Alan Boyd, Managing Director, alanboyd consultants ltd Gregg Sando, CEO, Cell Medica Limited Andrew L. Pecora, MD, Chairman of the Board, Acting CEO, Amorcyte Kim Raineri, Director, Cell Therapy Operations, Lonza Bioscience Christine V. Sapan, PhD, Executive Vice President & Chief Development Officer, Neurologix, Inc Bryan T. Butman, PhD, Senior Vice President, Vector Operations, GenVec, Inc Dr Lincoln Tsang, Partner, Arnold & Porter LLP, London Professor Sander van Deventer, CSO, AMT BV Henrik Ørum, MSc, PhD, Vice President & CSO, Santaris Pharma A/S Dr Robert A. Preti, President & Chief Scientific Officer, Progenitor Cell Therapy Dr Michael Schuster, Vice President, Operations, Angioblast Systems, Inc Dr Christopher Bravery, Director of Regulatory Affairs - Advanced Therapy Medicinal Products, ERA Consulting Group Dr Scott R. Burger, Principal, Advanced Cell & Gene Therapy Wei Liang, PhD, Pharmacologist, Division of Clinical Evaluation & Pharmacology/Toxicology, OCTGT/CBER, US Food & Drug Administration Dr Yen Choo, Founder & CEO, Plasticell Elyse Seltzer, MD, Chief Medical Officer, Vice President, Clinical Development & Medical Affairs, Tengion, Inc Donna R. Rill, BS, MT (ASCP), Vice President of Operations, Opexa Therapeutics Anthony G. Coia, MD, Principal, BioVentures Investors Dr Wilfried Dalemans, Vice President, Regulatory Affairs & Corporate Quality, TiGenix NV Jack Harvey MPH, Director of Manufacturing, Pervasis Therapeutics, Inc Dr Brett I. W. Zbar, Partner, Aisling Capital Dr Kai Pinkernell, Senior Director, Regenerative Cell Technology, Cytori Therapeutics, Inc Dr Andra Miller, Director, Cell & Gene Therapies, Biologics Consulting Group, Inc Dr Weng Tao, Chief Scientific Officer & Vice President, R&D, Neurotech Linda G. Strause, PhD, Executive Director, Oncology Clinical Operations, Vical Incorporated Michael Covington, Senior Director of Quality Assurance, Dendreon Corporation Marco Dieci, BSc, Quality & Regulatory Director, Qualified Person, MolMed SpA Vickie Sheckler, Associate Director, Regulatory Affairs, Novocell, Inc Penny Johnson, BSc, MSc, Phd, Director of Research, UK, Intercytex Ltd Visit this page again soon to find out who else you will be able to hear from – and meet – in Washington this coming January.
|
 |
